| 產品編號 | bs-55166R |
| 英文名稱 | [KO驗證抗體] PDCD4 |
| 中文名稱 | 凋亡相關蛋白4抗體 |
| 別 名 | PDCD-4; PDCD 4; Death up-regulated gene protein; Dug; H731; Ma3; MGC33046; MGC33047; Neoplastic transformation inhibitor; Neoplastic transformation inhibitor protein; Nuclear antigen H731; Nuclear antigen H731 like; Nuclear antigen H731 like protein; PDCD 4; Programmed cell death 4; programmed cell death 4 (neoplastic transformation inhibitor); Programmed cell death protein 4; Protein 197/15a; Protein MA-3; RP11 348N5.4; Tis; Nuclear antigen H731-like; Pdcd4; PDCD4_HUMAN; Topoisomerase-inhibitor suppressed protein; Topoisomerase-inhibitor suppressed protein (programmed cell death 4). |
| 研究領域 | 腫瘤 細胞生物 染色質和核信號 表觀遺傳學 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, (predicted: Mouse, ) |
| 產品應用 | WB=1:500-2000 IHC-P=1:400-800 （石蠟切片需做抗原修復）
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 51kDa |
| 細胞定位 | 細胞核 細胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Recombinant human PDCD4: 1-260/469 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
This gene encodes a protein localized to the nucleus in proliferating cells. Expression of this gene is modulated by cytokines in natural killer and T cells. The gene product is thought to play a role in apoptosis but the specific role has not yet been determined. Two transcripts encoding different isoforms have been identified. Alternative names: H731; MGC33046; MGC33047; Neoplastic transformation inhibitor; Neoplastic transformation inhibitor protein; Nuclear antigen H731; Nuclear antigen H731 like; Nuclear antigen H731 like protein; OTTHUMP00000020483; PDCD 4; Programmed cell death 4; programmed cell death 4 (neoplastic transformation inhibitor) ; Programmed cell death protein 4; Protein 197/15a ; RP11 348N5.4 . Function: Inhibits translation initiation and cap-dependent translation. May excert its function by hindering the interaction between EIF4A1 and EIF4G. Inhibits the helicase activity of EIF4A. Modulates the activation of JUN kinase. Down-regulates the expression of MAP4K1, thus inhibiting events important in driving invasion, namely, MAPK85 activation and consequent JUN-dependent transcription. May play a role in apoptosis. Tumor suppressor. Inhibits tumor promoter-induced neoplastic transformation. Binds RNA (By similarity). Subunit: Interacts (via MI domains) with EIF4A2 (By similarity). Interacts (via MI domains) with EIF4A1 (via N-terminal domain). Heterotrimer with EIF4A1; one molecule of PDCD4 binds two molecules of EIF4A1. Interacts with EIF4G1. May form a complex with EIF4A1 and EIF4G1. The interaction between PDCD4 and EIF4A1 interferes with the interaction between EIF4A1 and EIF4G. When phosphorylated, interacts with BTRC and FBXW11. Subcellular Location: Nucleus. Cytoplasm. Note=Shuttles between the nucleus and cytoplasm. Predominantly nuclear under normal growth conditions, and when phosphorylated at Ser-457. Exported from the nucleus in the absence of serum. Tissue Specificity: Up-regulated in proliferative cells. Highly expressed in epithelial cells of the mammary gland. Reduced expression in lung cancer and colon carcinoma. Post-translational modifications: Polyubiquitinated, leading to its proteasomal degradation. Rapidly degraded in response to mitogens. Phosphorylation of the phosphodegron promotes interaction with BTRC and proteasomal degradation. Phosphorylated at Ser-67 by RPS6KB1 in response to mitogens; phosphorylation promotes proteasomal degradation of PDCD4. Similarity: Belongs to the PDCD4 family. Contains 2 MI domains. SWISS: Q53EL6 Gene ID: 27250 Database links: Entrez Gene: 27250 Human Entrez Gene: 18569 Mouse Omim: 608610 Human SwissProt: Q53EL6 Human SwissProt: Q61823 Mouse Unigene: 711490 Human Unigene: 1605 Mouse Unigene: 375091 Mouse Unigene: 206228 Rat 程序性細胞死亡因子4是近期發現一種新的抑癌基因，在很多腫瘤組織中有不同的表達。 |
| 產品圖片 |
Sample:
Lane 1: Hela (Human) Cell Lysate at 25 ug Lane 2: PDCD4 knockout (KO) Hela (Human) Cell Lysate at 25 ug Primary: Anti-PDCD4 (bs-55166R) at 1/1000 dilution Secondary: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution Predicted band size: 60 kD Observed band size: 60 kD 
Sample:
Lane 1: Hela (Human) Cell Lysate at 30 ug Lane 2: 293T (Human) Cell Lysate at 30 ug Lane 3: MCF-7 (Human) Cell Lysate at 30 ug Lane 4: HepG2 (Human) Cell Lysate at 30 ug Primary: Anti-PDCD4 (bs-55166R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 60 kD Observed band size: 58 kD 
Paraformaldehyde-fixed, paraffin embedded (human placenta); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (PDCD4) Polyclonal Antibody, Unconjugated (bs-55166R) at 1:25 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
Paraformaldehyde-fixed, paraffin embedded (human thyroid cancer); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with (PDCD4) Polyclonal Antibody, Unconjugated (bs-55166R) at 1:25 overnight at 4°C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
